WebDyax is a Biotechnology Research, Biopharma, and Biotechnology company located in Burlington, Massachusetts with 67 employees. Find top employees, contact details and business statistics at RocketReach. ... These include use of DX-88 for the reduction of blood loss during surgery in collaboration with Cubist Pharmaceuticals (Cubist), and for ... WebApr 6, 2015 · /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Investor-Edge has initiated coverage on the following equities:...
Takeda Pharmaceutical Company - Wikipedia
WebNov 2, 2015 · Dyax stock traded up nearly 30% Monday morning at $35.76, after posting a new 52-week high of $36.67 billion. The stock's 52-week low is $12.11 and the consensus price target is $31.38. Related ... http://investors.shire.com/recent-acquisitions/proposed-dyax-corp-acquisition.aspx irs advertising
Dyax - Crunchbase Company Profile & Funding
WebRead More drug designation in patients 12 years of age and older. The firm is also investigating the drug for use in treating other types of angioedema and working to … WebOct 2, 2008 · Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development. Dyax's lead product candidate is DX-88 (ecallantide), a recombinant small protein that is currently being evaluated for its therapeutic potential in two separate indications. On September 24, … WebTakeda Pharmaceuticals was founded in 1781, and was incorporated on January 29, 1925. [12] One of the firm's mainstay drugs is Actos ( pioglitazone ), a compound in the thiazolidinedione class of drugs used in the treatment of type 2 … irs advanced ctc